August 2020 – Page 4 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2020-08-16

Pharmacological activation of NRF2 could be a way to combat Acute respiratory distress syndrome caused by SARSCoV2.

Acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 is largely the result of a dysregulated host response, followed by damage to alveolar cells and lung fibrosis. Exacerbated proinflammatory cytokines release (cytokine storm) and loss of T lymphocytes (lymphopenia) characterize the most aggressive presentation. A multifaceted anti-inflammatory strategy, based on pharmacological activation of nuclear factor erythroid

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-16

Important paper published on Cell by Morens and Fauci on Emerging Pandemic Diseases: How We Got To COVID-19

Infectious diseases prevalent in humans and animals are caused by pathogens that once emerged from other animal hosts. In addition to these established infections, new infectious diseases periodically emerge. In extreme cases they may cause pandemics such as COVID-19; in other cases, dead end infections or smaller epidemics result. Established diseases may also re-emerge, for

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-16

Defined the role of neutrophil extracellular traps in COVID-19 vascular occlusion. Efficacy of desamethasone, heparin and convalescent plasma.

Two papers recently published on EBioMedicine confirm that the excessive NET formation drives immunopathology in severe COVID-19 associated disseminated pulmonary intravascular coagulopathy. Coronavirus induced disease 2019 (COVID-19) can be complicated by severe organ damage leading to dysfunction of the lungs and other organs. The processes that trigger organ damage in COVID-19 are incompletely understood. Samples

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-15

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Important study on T cells in SARSCoV2 published in Cell from Marcus Buggert et al. CIM Sweden Karolinska Institute. SARS-CoV-2-specific memory T cells will likely prove critical for long-term immune protection against COVID-19. In this paper are systematically mapped the functional and phenotypic landscape of SARS-CoV-2-specific T cell responses in unexposed individuals, exposed family members,

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-07

SnapShot: Enveloped Virus Entry shown in Cell Journal

In order to initiate successful infection, viruses have to transmit and deliver their genome from one host cell or organism to another. To achieve this, enveloped viruses must first fuse their membrane with those of the target host cell. Here, it’s described the sequence of events leading to the entry of representative enveloped viruses, highlighting

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-07

Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. Meta-analysis shows 57% mortality reduction.

With the ongoing COVID-19 pandemic continuing to spread to hundreds of thousands the world over, scientists are still seeking an effective treatment or vaccine. Now, a new study published on the preprint server medRxiv* in July 2020 reports that an older treatment modality, namely, the use of convalescent antibody-rich plasma, brings down the mortality rate in

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-05

Half of low-income communities have no ICU beds. Income Disparities In Covid-19 Access To Critical Care Services

Policies that facilitate hospital coordination are urgently needed to mitigate effects of the COVID-19 pandemic A new Penn Medicine study sheds light on yet another reason why the coronavirus pandemic is disproportionately killing the poor: Residents in low-income neighborhoods lack access to intensive care unit (ICU) beds. While the shortage of ICU beds in the

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-05

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

It usually takes more than a decade to develop a safe, effective anti-viral therapy. But, when it comes to coronavirus disease 2019 (COVID-19), we don’t have that kind of time. One way to speed the process may be to put some old drugs to work against this new disease threat. This is generally referred to

No Comments InCovid-19

PIER MARIA FORNASARI
2020-08-05

NIH will test synthetic monoclonal antibodies and other experimental therapeutics for mild and moderate COVID-19

Initial clinical trial to determine if monoclonal antibodies can shorten severity of COVID-19 in outpatients. Source NIH A Phase 2 clinical trial will evaluate the safety and efficacy of potential new therapeutics for COVID-19, including an investigational therapeutic based on synthetic monoclonal antibodies (mAbs) to treat the disease. Researchers sponsored by the National Institute of

No Comments InCovid-19

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Archives: 2020-08-16

Pharmacological activation of NRF2 could be a way to combat Acute respiratory distress syndrome caused by SARSCoV2.

Important paper published on Cell by Morens and Fauci on Emerging Pandemic Diseases: How We Got To COVID-19

Defined the role of neutrophil extracellular traps in COVID-19 vascular occlusion. Efficacy of desamethasone, heparin and convalescent plasma.

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

SnapShot: Enveloped Virus Entry shown in Cell Journal

Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. Meta-analysis shows 57% mortality reduction.

Half of low-income communities have no ICU beds. Income Disparities In Covid-19 Access To Critical Care Services

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

NIH will test synthetic monoclonal antibodies and other experimental therapeutics for mild and moderate COVID-19